Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

TherapeuticsMD (TXMD) Net Cash Flow (2016 - 2026)

TherapeuticsMD filings provide 17 years of Net Cash Flow readings, the most recent being $944000.0 for Q1 2026.

On a quarterly basis, Net Cash Flow rose 35.05% to $944000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $2.7 million, a 28.65% increase, with the full-year FY2025 number at $2.5 million, up 109.74% from a year prior.
Net Cash Flow hit $944000.0 in Q1 2026 for TherapeuticsMD, up from $375000.0 in the prior quarter.
In the past five years, Net Cash Flow ranged from a high of $19.5 million in Q3 2022 to a low of -$140.8 million in Q2 2022.
Median Net Cash Flow over the past 5 years was -$71000.0 (2024), compared with a mean of -$14.3 million.
Biggest five-year swings in Net Cash Flow: crashed 437.54% in 2022 and later skyrocketed 2105.88% in 2025.
TherapeuticsMD's Net Cash Flow stood at -$81.8 million in 2022, then soared by 96.38% to -$3.0 million in 2023, then surged by 100.57% to $17000.0 in 2024, then skyrocketed by 2105.88% to $375000.0 in 2025, then soared by 151.73% to $944000.0 in 2026.
The last three reported values for Net Cash Flow were $944000.0 (Q1 2026), $375000.0 (Q4 2025), and $999000.0 (Q3 2025) per Business Quant data.